Analysis Biovica: Positive results in run-up to FDA process

New results provide clinical evidence for the DiviTum test in evaluating efficacy of breast cancer treatment palbociclib. Biovica expects FDA to provide clarity on requirements for clinical validation during the summer. This in turn will determine the lead time for market clearance.

Read the full report (Swedish) here.